Experimental Data for a Novel Inflammation-Targeting Drug Conjugate

ELN28-135-01 is a rationally designed bifunctional drug conjugate targeting soluble TNF-α and Janus kinase pathways. The dataset, created by Euan Murray and shared on figshare in April 2026, contains experimental results from in vitro and in vivo studies of this novel therapeutic candidate.

Use Cases

• Analyze linker cleavage efficiency data from neutrophil elastase assays to model protease-dependent drug release.
• Correlate in vitro TNF-α neutralization potency measurements with in vivo pharmacodynamic control outcomes from preclinical inflammation models.
• Compare exposure levels of free tofacitinib payload between the conjugate and nonconjugated anti-TNF-α comparator treatments.

Strengths

• Data supports a novel, rationally designed drug candidate (ELN28-135-01) with a specific mechanism of action.
• Findings are validated across multiple experimental contexts, including human PBMC assays and preclinical models of acute and chronic inflammation.

Limitations

• The dataset is extremely small at 1.3 KB, indicating very limited scope and likely a summary of key results rather than raw experimental data.
• Specific experimental parameters, raw measurements, and column definitions are not provided, limiting detailed re-analysis.

Provenance

Source

Euan Murray via figshare.

Collection Method

Experimental data from rational drug design, synthesis, and validation in biochemical, cellular, and animal models.

Freshness

Last updated in April 2026, indicating it is a forward-looking or planned dataset.